Methotrexate for psoriasis

Clinical and Experimental Dermatology

Volumn 21, Issue 6, 1996, Pages 399-408

  Boffa, M J ^a,b   Chalmers, R J G ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b ST LUKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; ETRETINATE; METHOTREXATE; METHOXSALEN; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYTOIN; PROBENECID; PYRIMETHAMINE; RETINOID; TRIMETHOPRIM;

BONE MARROW SUPPRESSION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INFORMATION; DRUG MECHANISM; DRUG MONITORING; GASTROINTESTINAL TOXICITY; HUMAN; LIVER TOXICITY; PRESCRIPTION; PRIORITY JOURNAL; PSORIASIS; REVIEW; SIDE EFFECT;

EID: 0030433002     PISSN: 03076938     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2230.1996.tb00142.x     Document Type: Review

References (113)

1. Ryan TJ, Vickers HR, Salem SN et al. The treatment of psoriasis with folic acid antagonists. Br J Dermatol 1964; 76: 555-64.
2. Ryan TJ, Baker H. Systemic corticosteroids and folic acid antagonists in the treatment of generalised pustular psoriasis: evaluation and prognosis based on the study of 104 cases. Br J Dermatol 1969; 81: 134-45.
3. Rosenbaum MM, Roenigk HH Jr. Treatment of generalised pustular psoriasis with etretinate (Ro 10-9359) and methotrexate. J Am Acad Dermatol 1984; 102: 357-61.
4. Collins P, Rogers S. The efficacy of methotrexate in psoriasis - a review of 40 cases. Clin Exp Dermatol 1992; 17: 257-60.
5. Black RL, O'Brien WM, Van Scott EJ et al. Methotrexate therapy in psoriatic arthritis. J Am Med Assoc 1964; 189: 743-7.
6. Zachariae H, Zachariae E. Methotrexate treatment of psoriatic arthritis. Acta Derm Venereol (Stockh) 1987; 67: 270-3.
7. Espinoza LR, Zakraoui L, Espinoza CG et al. Psoriatic arthritis: clinical response and side effects to methotrexate therapy. J Rheumatol 1992; 19: 872-7.
8. Boffa MJ, Chalmers RJG, Haboubi NY et al. Sequential liver biopsies during long-term methotrexate treatment for psoriasis: a reappraisal. Br J Dermatol 1995; 133: 774-8.
9. Al-Awadhi A, Dale P and McKendry RJ. Pancytopenia associated with low dose methotrexate therapy. A regional survey. J Rheumatol 1993; 20: 1121-5.
10. Dahl MGC, Gregory MM, Scheuer PJ. Methotrexate hepatotoxicity in psoriasis - comparison of different dosage regimens. Br Med J 1972; 1: 654-6.
11. Weinstein GD, Roenigk H, Maibach HI et al. Psoriasis -liver-methotrexate interactions. Arch Dermatol 1973; 108: 36-42.
12. Shapiro HA, Trowbridge JO, Lee JC, Maibach HI. Liver disease in psoriatics - an effect of methotrexate therapy? Arch Dermatol 1974; 110: 547-51.
13. Van de Kerkhof PCM, Hoefnagels WHL et al. Methotrexate maintenance therapy and liver damage in psoriasis. Clin Exp Dermatol 1985; 10: 194-200.
14. Van Dooren-Greebe RJ, Kuijpers ALA, Mulder J et al. Methotrexate revisited: effects of long-term treatment in psoriasis. Br J Dermatol 1994; 130: 204-10.
15. Kaplan MM. Methotrexate hepatotoxicity and the premature reporting of Mark Twain's death: both greatly exaggerated. Hepatology 1990; 2: 784-6.
16. Watson RGP, Smallwood RA. Low-dose methotrexate therapy and hepatotoxicity. The view of the hepatologist. Med J Aust 1991; 155: 428-30.
17. Bleyer WA. The clinical pharmacology of methotrexate: new applications of an old drug. Cancer 1978; 41: 36-51.
18. Olsen EA. The pharmacology of methotrexate. J Am Acad Dermatol 1991; 25: 306-18.
19. Weinstein GD, Frost P. Methotrexate for psoriasis - a new therapeutic schedule. Arch Dermatol 1971; 103: 33-8.
20. Ive FA, DeSaram CFW. Methotrexate and the citrovorum factor in the treatment of psoriasis. Trans St Johns Hosp Dermatol Soc 1970; 56: 45-7.
21. Burkhart CG. Treatment of psoriasis with methotrexate and folinic acid. J. Am Acad Dermatol 1980; 3: 207-8.
22. Tugwell P, Bennett K, Gent M. Methotrexate in rheumatoid arthritis. Ann Intern Med 1987; 107: 358-66.
23. Metzger AL, Bohan A, Goldberg LS. Polymyositis and dermatomyositis: combined methotrexate and corticosteroid therapy. Ann Intern Med 1974; 81: 182-9.
24. Kozarek RA, Patterson DJ, Gelfand MD et al. Methotrexate induces clinical and histological remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989; 110: 353-6.
25. Mullarkey MF, Blumenstein BA, Anrade WP et al. Methotrexate in the treatment of corticosteroid-dependent asthma: a double-blind cross over study. N Engl J Med 1988; 318: 603-7.
26. Kaplan M, Knox T. Treatment of primary biliary cirrhosis with low dose weekly methotrexate. Gastroenterology 1991; 101: 1332-8.
27. Jeffes EWB, McCullough JL, Pittelkow MR et al. Methotrexate therapy of psoriasis: differential sensitivity of proliferating lymphoid and epithelial cells to the cytotoxic and growth-inhibitory effects of methotrexate. J Invest Dermatol 1995; 104: 183-8.
28. Baker B, Griffiths C, Sambert S. The effects of cyclosporin A on T lymphocyte and dendritic cell subpopulations in psoriasis. Br J Dermatol 1987; 116: 503-10.
29. Gommans JM, Van Hezik SJTM, Van Huystee BEWL. Flow cytometric quantification of T6-positive cells in psoriatic epidermis after PUVA and methotrexate therapy. Br J Dermatol 1987; 116: 661-6.
30. Cream JJ, Poll DS. The effect of methotrexate and hydroxyurea on neutrophil chemotaxis. Br J Dermatol 1980; 102: 557-63.
31. Walsdorfer U, Cristophers E, Schroder JM. Methotrexate inhibits polymorphonuclear leucocyte chemotaxis in psoriasis. Br J Dermatol 1983; 108: 451-6.
32. Lammers AM, van de Kerkhof PCM, Mier PD. Reduction of leukotriene B4-induced intraepidermal accumulation of polymorphonuclear leucocytes by methotrexate in psoriasis. Br J Dermatol 1987; 116: 667-71.
33. Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 1993; 92: 2675-82.
34. Ternowitz T, Bjerring, Andersen PH et al. Methotrexate inhibits the human C5a-induced skin response in patients with psoriasis. J Invest Dermatol 1987; 89: 192-6.
35. Miller LC, Cohen FE, Orencole SF et al. Interleukin-1 beta is structurally related to dihydrofolate reductase: effects of methotrexate on IL-1. Lymphokine Res 1988; 7: 272.
36. Brody M, Bohm I, Bauer R. Mechanism of action of methotrexate: experimental evidence that methotrexate blocks the binding of interleukin 1 beta to the interleukin 1 receptor on target cells. Eur J Chem Clin Biochem 1993; 31: 667-74.
37. Lisby G, Avnstorp C, Wantzin GL. Interleukin-1: A new mediator in dermatology. Int J Dermatol 1987; 26: 8-12.
38. Schornagel JH, MeVie JG. The clinical pharmacology of methotrexate. Cancer Treatment Rev 1983; 10: 53-75.
39. Evans WE, Christensen ML. Drug interactions with methotrexate. J Rheumatol 1985; 12: 15-20.
40. Liddle BJ, Marsden JR. Drug interactions with methotrexate. Br J Dermatol 1989; 120: 582-3.
41. Bourke RS, Chheda G, Bremer A et al. Inhibition of renal tubular transport of methotrexate by probenecid. Cancer Res 1975; 35: 110-16.
42. Neirenberg DW, Mamelok RD. Toxic reaction to methotrexate in a patient receiving penicillin and furosemide. Arch Dermatol 1983; 119: 449-50.
43. Taylor JR, Halprim JM. Effect of sodium salicylate and indomethacin on methotrexate-serum albumin binding. Arch Dermatol 1977; 113: 588-91.
44. Anonymous. Lederle and Pharmacia methotrexate data Sheets. In: ABPI Data Sheet Compendium. London, Datapharm Publications Ltd, 1995; 797-800, 1291-2.
45. Thomas MH, Gutterman LA. Methotrexate toxicity in a patient receiving trimethoprim-sulfamethoxazole. J Rheumatol 1986; 13:440-1.
46. Thomas DR, Dover JS, Camp RDR. Pancytopenia induced by the interaction between methotrexate and trimethoprim-sulfamethoxazole. J Am Acad Dermatol 1987; 17: 1055-66.
47. Maricic M, Davis M, Gall EP. Megaloblastic pancytopenia in a patient receiving concurrent methotrexate and trimethoprim-sulfamethoxazole treatment. Arthritis Rheum 1986; 29: 133-5.
48. Groenendal H, Rampen FHJ. Methotrexate and trimethoprim-sulfamethoxazole - a potentially hazardous combination. Clin Exp Dermatol 1990; 15: 358-60.
49. Singh RR, Malaviya AN, Pandey JN et al. Fatal interaction between methotrexate and naproxen. Lancet 1986; i: 1390.
50. Daly HM, Scott GL, Boyle J, Roberts CJ. Methotrexate toxicity precipitated by azapropazone. Br J Dermatol 1986; 114: 733-5.
51. Maiche AG. Acute renal failure due to concomitant action of methotrexate and indomethacin. Lancet 1986; i: 1390.
52. Thyss A, Milano G, Kubar J et al. Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen. Lancet 1986; i: 256-8.
53. Gabrielli A, Leoni P, Danieli G. Methotrexate and non-steroidal anti-inflammatory drugs. Br Med J 1987; 294: 776.
54. Todd PA. Diclofenac sodium: a reappraisal of its properties. Drugs 1988; 35: 244-85.
55. Burton JL. Drug interactions with methotrexate. Br J Dermatol 1991; 124: 300-1.
56. Beck H-I, Foged EK. Toxic hepatitis due to combination therapy with methotrexate and etretinate in psoriasis. Dermatolagica 1983; 167: 94-6.
57. Zachariae H. Methotrexate and etretinate as concurrent therapies in the treatment of psoriasis. Arch Dermatol 1984; 120: 155.
58. Anderson PA, West SG, O'Dell JR et al. Weekly pulse methotrexate in rheumatoid arthritis: clinical and immunologic effects on a randomized, double-blind study. Ann Intern Med 1985; 103: 489-96.
59. Allison J. Methotrexate and smallpox vaccination. Lancet 1968; ii: 1250.
60. Nyfors A. Methotrexate therapy of psoriasis. Dan Med Bull 1980; 27: 74-96.
61. Milunsky A, Graef JW, Gaynor MF Jr. Methotrexate-induced congenital malformations. J Pediatr 1968; 72: 790-5.
62. Powell HR, Ekert H. Methotrexate-induced congenital malformations. Med J Austr 1971; 2: 1076-7.
63. Roenigk HH, Auerbach R, Maibach HI, Weinstein GD. Methotrexate in psoriasis: revised guidelines. J Am Acad Dermatol 1988; 19: 145-56.
64. Perry WH. Methotrexate and teratogenesis. Arch Dermatol 1983; 119: 874.
65. Frank L, Lichtman H, Petrou P. Experiences with methotrexate in psoriasis. Dermatologica 1968; 137: 87-96.
66. Weinstein GD. Methotrexate. Ann Intern Med 1977; 86: 199-204.
67. Kroner TH, Tschumi A. Conception of normal child during chemotherapy of acute lymphoblastic leukaemia in the father. Br Med J 1977; 1: 1322-3.
68. Melnyk J, Duffy DM, Sparkes RS. Human mitotic and meiotic chromosome damage following in vivo exposure to methotrexate. Clin Genet 1971; 11: 28-31.
69. Krogh Jensen M, Nyfors A. Cytogenetic effect of methotrexate on human cells in vivo: comparison between results obtained by chromosome studies on bone-marrow cells and blood lymphocytes and by the micronucleus test. Mutat Res 1979; 64: 339-43.
70. Sussman A, Leonard JM. Psoriasis, methotrexate, and oligospermia. Arch Dermatol 1980; 116: 215-17.
71. Morris LF, Harrod MJ, Menter MA, Silverman AK. Methotrexate and reproduction in men; Case report and recommendations. J Am Acad Dermatol 1993; 29: 913-16.
72. Duvic M, Johnson TM, Rapini RP et al. Acquired immunodeficiency syndrome-associated psoriasis and Reiter's syndrome. Arch Dermatol 1987; 123: 1622-32.
73. Gilbert SC, Klintmalm G, Menter A et al. Methotrexate-induced cirrhosis requiring liver transplantation in three patients with psoriasis. Arch Intern Med 1990; 150: 889-91.
74. Rebora A. Is methotrexate liver toxicity modest worldwide? Br J Dermatol 1996; 135: 1003-4.
75. Boffa MJ, Chalmers RJG, Haboubi NY et al. Is methotrexate liver toxicity modest worldwide? - a reply. Br J Dermatol 1996; 135: 1004.
76. Camp RDR. Methotrexate. In: Champion RH, Burton JL, Ebling FJG, eds, Textbook of Dermatology 5th edn, Vol. 2. Oxford: Blackwell Scientific Publications, 1992; 1424-7.
77. Zanolli MD, Sherertz EF, Hedberg AE. Methotrexate: anti-inflammatory or antiproliferative? J Am Acad Dermatol 1990; 22: 523-4.
78. Roenigk HH Jr, Auerbach R, Bergfeld WF et al. A cooperative prospective study of the effects of psoriasis on liver biopsies. In: Farber EM, Cox AJ, eds. Psoriasis: Proceedings of the Second International Symposium. New York: Yorke Medical Books, 1977; 243-8.
79. Weismann K. Methotrexate therapy for psoriasis in elderly patients with impaired renal function. Acta Derm Venereol (Stockh) 1977; 57: 185.
80. Fairris GM, Dewhurst AG, White JE et al. Methotrexate dosage in patients aged over 50 with psoriasis. Br Med J 1989; 298: 801-2.
81. Hendel J, Nyfors A. Impact of methotrexate therapy on the folate status of psoriatic patients. Clin Exp Dermatol 1985; 10: 30-5.
82. Weinstein GD, Roenigk H, Maibach HI et al. Psoriasis-liver-methotrexate interactions. Arch Dermatol 1973; 108: 36-42.
83. Mitchell DM, Johnson RJ, Testa HJ et al. Ultrasound and radionuclide scans - poor indicators of liver damage in psoriatic patients treated with methotrexate. Clin Exp Dermatol 1987; 12: 243-5.
84. Rademaker M, Webb JAW, Lowe DG et al. Magnetic resonance imaging as a screening procedure for methotrexate induced liver damage. Br J Dermatol 1987; 117: 311-16.
85. Geronemus RG, Auerbach R, Tobias H. Liver biopsies v liver scans in methotrexate-treated patients with psoriasis. Arch Dermatol 1982; 118: 649-51.
86. McHenry PM, Bingham EA, Callender ME et al. Dynamic hepatic scintigraphy in the screening of psoriatic patients for methotrexate-induced hepatotoxicity. Br J Dermatol 1992; 127: 122-5.
87. Lanse SB, Arnold GL, Gowans JDC, Kaplan MM. Low incidence of hepatotoxicity associated with long-term low-dose, oral methotrexate in treatment of refractory psoriasis, psoriatic arthritis and rheumatoid arthritis: an acceptable risk/ benefit ratio. Dig Dis Sci 1985; 30: 104-9.
88. Creswell SN, Burrows D. Liver biopsies in psoriatics. Complications and evaluation. Int J Derm 1980; 19: 217-19.
89. Gilmore IT, Burroughs A, Murray-Lyon I et al. Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: an audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut 1995; 36: 437-41.
90. Risteli J, Sogaard H, Oikarinen A et al. Aminoterminal propeptide of type III procollagen in methotrexate-induced liver fibrosis and cirrhosis. Br J Dermatol 1988; 119: 321-5.
91. Mitchell DM, Smith A, Rowan B et al. Serum type III procollagen peptide, dynamic liver function tests and hepatic fibrosis in psoriatic patients receiving methotrexate. Br J Dermatol 1990; 122: 1-7.
92. Zachariae H, Muhammad Aslam H, Bjerring P et al. Serum aminoterminal propeptide of type III procollagen in psoriasis and psoriatic arthritis: relation to liver fibrosis and arthritis. J Am Acad Dermatol 1991; 25: 50-3.
93. Boffa MJ, Smith A, Chalmers RJG et al. The place of type III procollagen aminopeptide (PIIINP) measurement in the assessment of liver damage in methotrexate-treated psoriatic patients. Br J Dermatol 1995; 133 (Suppl. 45): 16-17.
94. Boffa MJ, Smith A, Chalmers RJG et al. Serum type III procollagen aminopeptide for assessing liver damage in methotrexate-treated psoriatic patients. Br J Dermatol 1996; 135: 538-44.
95. Duhra P. Treatment of gastrointestinal symptoms associated with methotrexate treatment for psoriasis. J Am Acad Dermatol 1993; 28: 466-9.
96. Weinblatt ME, Fraser P. Elevated mean corpuscular volume in methotrexate treated rheumatoid arthritis patients. Arthritis Rheum 1989; 32: 1592-6.
97. Morgan SL, Alarcon GS, Krumdieck CL. Folic acid supplementation during methotrexate therapy: it makes sense. J Rheumatol 1993; 20: 929-30.
98. Dodd HJ, Kirby JDT, Munro DD. Megaloblastic anaemia in psoriatic patients treated with methotrexate. Br J Dermatol 1985; 112: 630-1.
99. Zachariae H, Sogaard H. Methotrexate-induced liver cirrhosis - a follow up. Dermatologica 1987; 175: 178-82.
100. Ellman MH, Teffer MC, Turner AF et al. Benefit of G-CSF for methotrexate-induced neutropenia in rheumatoid arthritis. Am J Med 1992; 92: 337-8.
101. Bailin PL, Tindall JP, Roenigk HH et al. Is methotrexate therapy for psoriasis carcinogenic? A modified retrospective prospective analysis. J Am Med Assoc 1975; 232: 359-62.
102. Stern RS, Zierler S, Parrish JA. Methotrexate used for psoriasis and the risk of noncutaneous or cutaneous malignancy. Cancer 1982; 50: 869-72.
103. Nyfors A, Jensen H. Frequency of malignant neoplasm in 248 long-term methotrexate-treated psoriatics: a preliminary study. Dermatologica 1983; 167: 260-1.
104. Pointud P, Prudat M, Peron J-M. Acute leukaemia after low dose methotrexate therapy in a patient with rheumatoid arthritis. J Rheumatol 1993; 20: 1215-16.
105. Rustin GJS, Rustin F, Dent J et al. No increase in second tumours after cytotoxic chemotherapy for gestational trophoblastic tumours. N Engl J Med 1983; 308: 473-6.
106. Fitzsimons CP, Long J, MacKie RM. Synergistic carcinogenic potential of methotrexate and PUVA in psoriasis. Lancet 1983; i: 235-6.
107. Lindelof B, Sigurgeirsson B. PUVA and cancer: a case-controlled study. Br J Dermatol 1993; 129: 39-41.
108. Stern RS, Laird N. The carcinogenic risk of treatments for severe psoriasis. Cancer 1994; 73: 2759-64.
109. From E. Methotrexate pneumonitis in a psoriatic. Br J Dermatol 1975; 93: 107-10.
110. Phillips TJ, Hugh Jones D, Baker H. Pulmonary complications following methotrexate therapy. J Am Acad Dermatol 1987; 16: 373-5.
111. Kaplan RL, Waite DH. Progressive interstitial lung disease from prolonged methotrexate therapy. Arch Dermatol 1978; 114: 1800-2.
112. Lewis WL, Walker JF. Methotrexate-induced pulmonary fibrosis. Arch Dermatol 1979; 115: 1169-70.
113. Zachariae H, Hansen HE, Sogaard H, Steen Olsen T. Kidney biopsies in methotrexate-treated psoriatics. Dermatologica 1990; 181: 273-6.